{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:31:22Z","timestamp":1792297882551,"version":"4.4.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Following STRIDE-II recommendations, the discovery of novel noninvasive biomarkers, beyond the use of C-reactive protein (CRP) and fecal calprotectin, remains a medical need to further improve the monitoring of patients with inflammatory bowel disease (IBD). This study aims to evaluate the potential of serum lipopolysaccharide-binding protein (LBP) in monitoring IBD activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cross-sectional study included 69 IBD patients (43 Crohn\u2019s disease and 26 ulcerative colitis) and 82 controls. Serum LBP levels were measured by ELISA. Clinical, biological and endoscopic parameters were analyzed for IBD patients with no reports of missing data. Statistical tests, including nonparametric tests and receiver operating characteristic (ROC) curve analysis, were used to evaluate the diagnostic accuracy of LBP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      IBD patients displayed a significantly higher LBP median [29.6\u2005\u03bcg\/ml (19.8\u201338.8) in Crohn\u2019s disease and 22.8 (13.7\u201338.8) in ulcerative colitis] than controls [5.8 (4.7\u20137.3),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001] with little overlapping distributions. In Crohn\u2019s disease patients, LBP levels gradually increased with endoscopic activity scores demonstrating a 1.7-fold rise in active patients compared to remitter patients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.02). LBP level exhibited a positive correlation with CRP (\n                      <jats:italic toggle=\"yes\">\u03c1<\/jats:italic>\n                      \u2005=\u20050.75,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001) as well as fecal calprotectin (\n                      <jats:italic toggle=\"yes\">\u03c1<\/jats:italic>\n                      \u2005=\u20050.42,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.01), both of which further increased when excluding cases that did not match endoscopic activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>LBP might be a promising noninvasive biomarker for monitoring disease activity, especially in Crohn\u2019s disease patients. In clinical situations where current biomarkers lack sensitivity, LBP could be discriminative and help filling the gap for reliable therapeutic decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/meg.0000000000002811","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T06:14:33Z","timestamp":1720419273000},"page":"1093-1100","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Lipopolysaccharide-binding protein in Crohn\u2019s disease patients: a promising noninvasive biomarker monitoring disease activity"],"prefix":"10.1097","volume":"36","author":[{"given":"Louison D.","family":"Toris","sequence":"first","affiliation":[{"name":"Laboratory of Gastroenterology Experimental (LGE), Universit\u00e9 Libre de Bruxelles (ULB)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte F.","family":"Minsart","sequence":"additional","affiliation":[{"name":"Laboratory of Gastroenterology Experimental (LGE), Universit\u00e9 Libre de Bruxelles (ULB)"},{"name":"Department of Gastroenterology \u2013 Hepato-Pancreatology and Digestive Oncology, Universit\u00e9 libre de Bruxelles ULB \u2013 H\u00f4pital Universitaire de Bruxelles H.U.B \u2013 CUB H\u00f4pital Erasme, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile P.","family":"Husson","sequence":"additional","affiliation":[{"name":"Laboratory of Gastroenterology Experimental (LGE), Universit\u00e9 Libre de Bruxelles (ULB)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis P.","family":"Franchimont","sequence":"additional","affiliation":[{"name":"Laboratory of Gastroenterology Experimental (LGE), Universit\u00e9 Libre de Bruxelles (ULB)"},{"name":"Department of Gastroenterology \u2013 Hepato-Pancreatology and Digestive Oncology, Universit\u00e9 libre de Bruxelles ULB \u2013 H\u00f4pital Universitaire de Bruxelles H.U.B \u2013 CUB H\u00f4pital Erasme, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L.","family":"Liefferinckx","sequence":"additional","affiliation":[{"name":"Laboratory of Gastroenterology Experimental (LGE), Universit\u00e9 Libre de Bruxelles (ULB)"},{"name":"Department of Gastroenterology \u2013 Hepato-Pancreatology and Digestive Oncology, Universit\u00e9 libre de Bruxelles ULB \u2013 H\u00f4pital Universitaire de Bruxelles H.U.B \u2013 CUB H\u00f4pital Erasme, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"R1-20250801","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"R2-20250801","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ecco-jcc\/jjy138","article-title":"Bacteria-related events and the immunological response of onset and relapse adult crohn\u2019s disease patients.","volume":"13","author":"Cant\u00f3","year":"2019","journal-title":"J Crohns Colitis"},{"key":"R3-20250801","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn\u2019s disease.","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R4-20250801","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease.","volume":"361","author":"Abraham","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-20250801","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/gastro\/goy006","article-title":"Role of endoscopy in inflammatory bowel disease.","volume":"6","author":"Bharadwaj","year":"2018","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"R6-20250801","first-page":"345","article-title":"C-reactive protein and the acute phase response.","volume":"27","author":"Gewurz","year":"1982","journal-title":"Adv Intern Med"},{"key":"R7-20250801","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmed.2020.00123","article-title":"Serum biomarkers for inflammatory bowel disease.","volume":"7","author":"Chen","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R8-20250801","first-page":"77","article-title":"Faecal calprotectin.","volume":"39","author":"Pathirana","year":"2018","journal-title":"Clin Biochem Rev"},{"key":"R9-20250801","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.crohns.2009.09.008","article-title":"Does fecal calprotectin predict relapse in patients with Crohn\u2019s disease and ulcerative colitis?","volume":"4","author":"Garc\u00eda-S\u00e1nchez","year":"2010","journal-title":"J Crohns Colitis"},{"key":"R10-20250801","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1177\/2050640616686517","article-title":"Compliance with the faecal calprotectin test in patients with inflammatory bowel disease.","volume":"5","author":"Mar\u00e9chal","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"R11-20250801","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/imr.12671","article-title":"Dynamic balance of pro\u2010 and anti\u2010inflammatory signals controls disease and limits pathology.","volume":"285","author":"Cicchese","year":"2018","journal-title":"Immunol Rev"},{"key":"R12-20250801","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.2402637","article-title":"Structure and function of lipopolysaccharide binding protein.","volume":"249","author":"Schumann","year":"1990","journal-title":"Science"},{"key":"R13-20250801","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.4049\/jimmunol.163.5.2792","article-title":"Lipopolysaccharide binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response.","volume":"163","author":"Vreugdenhil","year":"1999","journal-title":"J Immunol"},{"key":"R14-20250801","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1007\/s00125-013-3015-9","article-title":"A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction.","volume":"56","author":"Moreno-Navarrete","year":"2013","journal-title":"Diabetologia"},{"key":"R15-20250801","doi-asserted-by":"crossref","first-page":"681810","DOI":"10.3389\/fimmu.2021.681810","article-title":"Effects of lipopolysaccharide-binding protein (LBP) single nucleotide polymorphism (SNP) in infections, inflammatory diseases, metabolic disorders and cancers.","volume":"12","author":"Meng","year":"2021","journal-title":"Front Immunol"},{"key":"R16-20250801","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000492778","article-title":"Serum lipopolysaccharide-binding protein is associated with chronic inflammation and metabolic syndrome in hemodialysis patients.","volume":"47","author":"Lim","year":"2019","journal-title":"Blood Purif"},{"key":"R17-20250801","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ibd.21402","article-title":"Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn\u02bcs disease.","volume":"17","author":"Lakatos","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R18-20250801","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ibd.20019","article-title":"Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease.","volume":"13","author":"Rojo","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R19-20250801","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD.","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"R20-20250801","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ajg.2009.545","article-title":"Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn\u2019s disease (SES-CD) than CRP, blood leukocytes, and the CDAI.","volume":"105","author":"Schoepfer","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R21-20250801","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1177\/2050640618784046","article-title":"Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice.","volume":"6","author":"Reenaers","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"R22-20250801","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/liv.13979","article-title":"Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis.","volume":"39","author":"Dhillon","year":"2019","journal-title":"Liver Int"},{"key":"R23-20250801","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/ar1392","article-title":"Influence of corticosteroids on C-reactive protein in patients with rheumatoid arthritis.","volume":"6","author":"Mysler","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"R24-20250801","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1097\/CCM.0b013e31817b86e3","article-title":"Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis?","volume":"36","author":"Sakr","year":"2008","journal-title":"Crit Care Med"},{"key":"R25-20250801","doi-asserted-by":"crossref","first-page":"e013628","DOI":"10.1161\/JAHA.119.013628","article-title":"Serum lipopolysaccharide\u2010binding protein levels and the incidence of cardiovascular disease in a general Japanese population: the Hisayama study.","volume":"8","author":"Asada","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R26-20250801","doi-asserted-by":"crossref","first-page":"e54600","DOI":"10.1371\/journal.pone.0054600","article-title":"Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity.","volume":"8","author":"Gonzalez-Quintela","year":"2013","journal-title":"PLoS One"},{"key":"R27-20250801","doi-asserted-by":"crossref","first-page":"G11","DOI":"10.1152\/ajpgi.00113.2021","article-title":"Biomarkers for assessment of intestinal permeability in clinical practice.","volume":"321","author":"Seethaler","year":"2021","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R28-20250801","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00535-022-01862-y","article-title":"A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation.","volume":"57","author":"Kishi","year":"2022","journal-title":"J Gastroenterol"},{"key":"R29-20250801","doi-asserted-by":"crossref","first-page":"723","DOI":"10.4253\/wjge.v8.i20.723","article-title":"Endoscopic evaluation in diagnosis and management of inflammatory bowel disease.","volume":"8","author":"Moran","year":"2016","journal-title":"World J Gastrointest Endosc"},{"key":"R30-20250801","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MEG.0000000000002681","article-title":"Intestinal barrier biomarkers in clinical evaluation of patients with inflammatory bowel disease.","volume":"36","author":"Mogilevski","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R31-20250801","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jgh3.12068","article-title":"Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn\u2019s disease activity.","volume":"2","author":"Zittan","year":"2018","journal-title":"JGH Open"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T17:02:12Z","timestamp":1754067732000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002811","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}